pioneer 6 oral semaglutide cardiovascular outcomes pioneer 6 results fig1.jpg Oral Semaglutide and Cardiovascular Outcomes

First approved dual GIP/ GLP-1 receptor agonist tirzepatide (Mounjaro) added to guidelines Stimulates incretin effect, promoting insulin secretion and glucose clearance after meals Rated very high efficacy for A1C% and weight reduction Cardiorenal benefit currently under investigation Subcutaneous injection administered once weekly Gastrointestinal adverse effects may occur initially and decrease over time See Section 9

However, its cardiovascular effects in non-obese, non-diabetic hypertension remain unclear

In the SCALE trial, the most common adverse events with liraglutide were nausea (40.2% vs

Mazdutide is another newer option, and the mazdutide versus tirzepatide comparison covers the differences in mechanism and early efficacy data